Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy

Area of Science:

• Cardiology
• Lipid Metabolism
• Preventive Medicine

Background:

• Low high-density lipoprotein cholesterol (HDL-C) is a significant risk factor for cardiovascular disease (CVD).
• Current guidelines do not recommend lipid-lowering therapy for patients with low HDL-C if low-density lipoprotein cholesterol (LDL-C) is not elevated.
• Many individuals with low HDL-C also present with other CVD risk factors, such as high LDL particle concentrations.

Purpose of the Study:

• To evaluate the potential benefits of statin therapy in patients with low HDL-C and LDL-C levels below target.
• To explore the role of statins in managing combined lipid abnormalities for CVD risk reduction.

Main Methods:

• This study reviews existing literature on statin therapy, HDL-C, and LDL-C levels.
• Analysis focuses on the impact of statins on LDL particle concentration and overall cardiovascular risk in specific patient populations.

Main Results:

• Statins are effective in lowering LDL-C and can increase HDL-C levels.
• Lowering LDL particle concentration is a key strategy for reducing cardiovascular risk.
• Extending statin use to patients with low HDL-C and below-target LDL-C may offer additional CVD risk reduction.

Conclusions:

• Statins demonstrate efficacy in managing dyslipidemia, including increasing HDL-C.
• Consideration of statin therapy for patients with low HDL-C and below-target LDL-C warrants further investigation for comprehensive CVD risk management.